Celltrion signs W135b contract with affiliate for Remsima

Published : Sept 20, 2016 - 17:47 Updated : Sept 20, 2016 - 17:51

◀ Back to List
More article by this Writer

[DISCLOSURE] Celltrion (068270) announced on Sept. 20 that it has signed a 134.9 billion won (US$120.40 million) contract with its affiliate Celltrion Healthcare to provide biosimilar antibody Remsima.

This amounts to 22.36 percent of its revenue last year and the contract expires on Sept. 30.

(theinvestor@heraldcorp.com)

◀ Back to List
More article by this Writer

LATEST NEWS

>

S. Korea not to attend Sado mine memorial: foreign ministry
>

[Weekender] Korea's traditional sauce culture gains global recognition
>

[What to Play] Cozy songs to warm you up
>

Toxins at 622 times legal limit found in kids' clothes from Chinese platforms
>

Gyeongju blends old with new
>

At Gwangcheonok, try North Korean-style sundae gukbap
>

Over 80,000 malicious calls made to Seoul call center since 2020
>

Trump picks ex-N. Korea policy official as his principal deputy national security adviser
>

BLACKPINK's Rose stays at No. 3 on British Official Singles chart with 'APT.'
>

What you need to know about Adani's US bribery indictment